Eli Lilly jettisons cancer contender after another Phase III failure

Ryan McBride The Indianapolis-based drug giant has slammed the brakes on development of enzastaurin, which failed to meet the main goal for boosting disease-free survival in a Phase ...

Civitas Parkinson’s drug improves motor fluctuations in Phase II trial

Emily Mullin Alkermes ($ ALKS) spinout Civitas Therapeutics today reported positive topline results from a Phase II clinical trial of its Parkinson's drug CVT-301, which ...
Page 11 of 11« First...7891011
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS